Related Experiment Video

Updated: Apr 15, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

19.6K

The nuclear translocation of ERK1/2 as an anticancer target

Alexander Plotnikov1, Karen Flores1, Galia Maik-Rachline1

  • 1Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel.

Nature Communications
|March 31, 2015
PubMed

Insights

A novel peptide blocks ERK1/2 nuclear translocation, inhibiting cancer cell proliferation and viability. This approach shows promise as a new therapeutic strategy for various ERK1/2-related cancers, including drug-resistant melanoma.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • Extracellular signal-regulated kinases (ERK1/2) are crucial for cell proliferation, primarily through nuclear translocation.
  • Cytoplasmic ERK1/2 activity regulates feedback loops, distinct from proliferation induction.
  • Targeting nuclear translocation offers a specific approach to inhibit proliferation without affecting other cellular processes.

Purpose of the Study:

  • To develop and validate a peptide-based inhibitor of ERK1/2 nuclear translocation.
  • To assess the therapeutic potential of this inhibitor against various cancer types, including drug-resistant melanoma.
  • To establish nuclear translocation of ERK1/2 as a viable drug target.

Main Methods:

  • Design and synthesis of an NTS-derived, myristoylated phosphomimetic peptide.
  • In vitro studies on melanoma and other cancer cell lines, including drug-resistant variants.
  • In vivo evaluation in xenograft models for efficacy against various cancers and melanoma recurrence.

Main Results:

  • The peptide effectively blocks importin7-ERK1/2 interaction, preventing nuclear translocation.
  • Demonstrated induction of apoptosis in melanoma cells and inhibition of viability in other cancer cells.
  • Showed significant efficacy in xenograft models, outperforming PLX4032 in preventing melanoma recurrence and overcoming resistance.

Conclusions:

  • The developed peptide is a potent inhibitor of ERK1/2 nuclear translocation.
  • Targeting ERK1/2 nuclear translocation is a promising strategy for treating diverse cancers.
  • This approach offers a new therapeutic avenue for drug-resistant and recurrent cancers.

More Related Videos

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.9K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K